Worries about drug-coated stents and competition from generic drugs have weighed on Johnson & Johnson. But its stock is still promising.
With medical devices, diagnostics, and consumer products, J&J is far more diversified than most pharmaceutical makers. In addition, it has increased its dividend for the past
44 years, generates a whopping $10 billion in free cash flow, and boasts an AAA credit rating.